1203590-31-1

Basic information

• Product Name: 4-benzyl-3-phenyl-piperazine-1-carboxylic acid tert-butyl ester
• Synonyms: 4-benzyl-3-phenyl-piperazine-1-carboxylic acid tert-butyl ester
• CAS NO: 1203590-31-1
• Molecular Weight: 352.477
• Mol File: 1203590-31-1.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 4-benzyl-3-phenyl-piperazine-1-carboxylic acid tert-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 4-benzyl-3-phenyl-piperazine-1-carboxylic acid tert-butyl ester(1203590-31-1)
• EPA Substance Registry System: 4-benzyl-3-phenyl-piperazine-1-carboxylic acid tert-butyl ester(1203590-31-1)

Safety Data

• Hazardous Substances Data: 1203590-31-1(Hazardous Substances Data)

Upstream product

• 5271-26-1 m-phenylpiperazine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 100-52-7 benzaldehyde 
• 502649-25-4 tert-butyl 4-(3-methoxy-4-(1H-pyrazol-4-yl)benzoyl)-3-phenylpiperazine-1-carboxylate 
• 108-86-1 bromobenzene 
• 57260-70-5 4-benzyl-piperazine-1-carboxylic acid tert-butyl ester 
• 1203590-16-2 4-hydroxy-3-phenyl-piperazine-1-carboxylic acid tert-butyl ester 
• 100-44-7 benzyl chloride 
• 100-39-0 benzyl bromide 

Downstream Products

• 5368-33-2 1-benzyl-2-phenyl-piperazine 

Relevant articles and documents

Piperazine squaric acid diamides, a novel class of allosteric P2X7 receptor antagonists

The P2X7 receptor (P2X7R) stands out among the purinergic receptors due to its strong involvement in the regulation of tumor growth and metastasis formation as well as in innate immune responses and afferent signal transmission. Numerous studies have pointed out the beneficial effects of P2X7R antagonism for the treatment of a variety of cancer types, inflammatory diseases, and chronic pain. Herein we describe the development of novel P2X7R antagonists, incorporating piperazine squaric diamides as a central element. Besides improving the antagonists’ potency from pIC50 values of 5.7–7.6, ADME properties (logD7.4 value, plasma protein binding, in vitro metabolic stability) of the generated compounds were investigated and optimized to provide novel P2X7R antagonists with drug-like properties. Furthermore, docking studies revealed the antagonists binding to the allosteric binding pocket in two distinct binding poses, depending on the substitution of the central piperazine moiety.

Complete regioselective addition of grignard reagents to pyrazine N-oxides, toward an efficient enantioselective synthesis of substituted piperazines

(Figure presented) A conceptually new one-pot strategy for the synthesis of protected substituted piperazines via the addition of Grignard reagents to pyrazine N-oxides is presented. This strategy is high yielding (33-91% over three steps), step-efficient, and fast. The synthesized N,N-diprotected piperazines are convenient to handle and allow for orthogonal deprotection at either nitrogen for selective transformations. In addition, this Is a synthetic route to enantiomerically enriched piperazines by using a combination of phenyl magnesium chloride and (-)-sparteine, which resulted In enantiomeric excesses up to 83%.